Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System

Hiroshima, Yuichi; TAMAKI, YOSHIO; SAWADA, TAKUYA; Ishida, Toshiki; Yasue, Kenji; Shinoda, Kazuya; Saito, Takashi; Kaburagi, Takayuki; Kiyoshima, Moriyuki; Okumura, Toshiyuki; Sakurai, Hideyuki

doi:10.21873/anticanres.15782

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies that have employed common doses and fractionations have reported mature follow-up data on SBRT for early-stage NSCLC, the findings of which are summarized in Table III. Two-year LC and OS rates in these studies were 91.9-100 and 54.6-84.8%, respectively (5)(6)(7)(8). Two-year LC and OS rates in the present study were 94.4 and 80.0%, which are consistent with these findings.…”

Section: Kaplan-meier Plot For the Local Control (Lc) (A) Cause-speci...supporting

confidence: 91%

Clinical Outcomes of Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer

Tasaki

Ashizawa

Nakamura

et al. 2023

CDP

View full text Add to dashboard Cite

Background/Aim: To investigate the clinical outcomes of stereotactic body radiotherapy (SBRT) in patients with early-stage non-small cell lung cancer (NSCLC). Patients and Methods: Among consecutive patients with early-stage NSCLC who received SBRT between November 2009 and September 2019, those with cT1-2N0M0 staged by the UICC TNM classification and staging system for lung cancer were retrospectively analyzed. Results: Fifty-three patients with early-stage NSCLC received SBRT. The median follow-up period was 29 months (range=2-105 months). Twenty-one lung tumors were clinically diagnosed as early-stage primary lung cancers without histological confirmation. Histological examinations revealed adenocarcinoma in 24 patients and squamous cell carcinoma in 8. Two- and 5-year local control, cancer-specific survival, progression-free survival (PFS), and overall survival (OS) rates were 94.4 and 94.4%; 94.6 and 90.8%; 69.0 and 43.3%; and 80.0 and 59.3%, respectively. In a univariate analysis, the T stage, histology, and type of pulmonary nodule correlated with PFS and OS. Conclusion: Good clinical outcomes were achieved by patients with early-stage NSCLC who received SBRT.

show abstract

Section: Kaplan-meier Plot For the Local Control (Lc) (A) Cause-speci...supporting

confidence: 91%

Clinical Outcomes of Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer

Tasaki

Ashizawa

Nakamura

et al. 2023

CDP

View full text Add to dashboard Cite

show abstract

“…The real-time tumor-tracking system with fiducial markers and fluoroscopic imaging can also be used to accurately treat lung tumors by monitoring fiducial markers within several millimeters of the gating window [5] . However, the monitoring accuracy of this system may be reduced because of dropouts and potential migration of fiducial markers during treatment [6] , [7] .…”

Section: Introductionmentioning

confidence: 99%

Statistical evaluation of the effectiveness of dual amplitude-gated stereotactic body radiotherapy using fiducial markers and lung volume

Tanabe

Tanaka

2022

Physics and Imaging in Radiation Oncology

View full text Add to dashboard Cite

“…In this study, the accuracy of the dynamic movement of the drive system was verified using SyncTraX® FX4 (Shimadzu, Kyoto, Japan). SyncTraX® FX4 is the new system used for tracking irradiation, 11 and in recent years, some technical 12,13 and clinical 14 evidences have validated its efficacy. In this verification, the driving accuracy of only one of the drive systems was tested (Stage‐1 only), assuming that both drive systems in the platform are equivalent in their accuracy because they have a similar structure.…”

Section: Methodsmentioning

confidence: 99%

Section: Dynamic Positioning Evaluationmentioning

confidence: 99%

Development of a dynamic motion platform with two independent drive systems for radiotherapy

Saito

Kawakami²,

Suzuki

et al. 2023

J Applied Clin Med Phys

View full text Add to dashboard Cite

Background: There are some motion platforms for radiotherapy quality assurance. However, no platform with two drive systems that can move along three axes is available. Purpose: The purpose of this study is to develop a dynamic motion platform with two drive systems capable of three-axis motion and to evaluate its motion performance. Methods: The developed moving platform had two drive systems that use the same equipment. Each axis of the platform used can support a maximum load of 10 kg. The motors for moving the platform in each direction are capable of a drive stroke up to 40 mm. The drive speed is 30 mm/s at maximum load fluctuation. To evaluate the static positional accuracy of this system with an arbitrary input movement, the XYZ position of each axis was measured using a coordinate measuring machine operating from 0 to 40 mm at 10 mm intervals. In addition, the accuracy of dynamic motion was verified with Sine waveform inputs of different patterns to the three axes for approximately 60 s, and they were compared with the resulting detected signals by SyncTrax. Results:The two drive systems were successfully operated on three axes by using independent control systems. For static position, the accuracies were within 0.2 mm, 0.05 mm, and 0.14 mm for lateral, longitudinal, and vertical directions, respectively. For dynamic motion, the mean absolute errors in the X, Y, and Z axes between the platform inputs and SyncTrax detected signals were 0.14 ± 0.10 mm, 0.16 ± 0.12 mm, and 0.16 ± 0.11 mm, respectively. Conclusions: A new dynamic platform for radiation therapy with two drive systems capable of three-axis motion was developed, and the positional accuracy of the drive axes was confirmed to be less than 0.2 mm.

show abstract

Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System

Cited by 8 publications

References 0 publications

Clinical Outcomes of Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer

Clinical Outcomes of Stereotactic Body Radiation Therapy for Early-stage Non-small Cell Lung Cancer

Statistical evaluation of the effectiveness of dual amplitude-gated stereotactic body radiotherapy using fiducial markers and lung volume

Development of a dynamic motion platform with two independent drive systems for radiotherapy

Contact Info

Product

Resources

About